ProMIS Neurosciences, Inc.
PMN
$0.5359
-$0.0131-2.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 438.18% | 157.29% | 94.36% | 124.46% | 61.66% |
| Gross Profit | -438.18% | -157.29% | -94.36% | -124.46% | -61.66% |
| SG&A Expenses | 31.90% | 28.52% | -210.46% | 36.03% | -42.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 275.31% | 102.90% | -35.42% | 76.15% | -6.42% |
| Operating Income | -275.31% | -102.90% | 35.42% | -76.15% | 6.42% |
| Income Before Tax | -285.60% | -102.14% | 93.35% | 492.94% | -13.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -285.60% | -102.14% | 93.35% | 492.94% | -13.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -285.60% | -102.14% | 93.35% | 492.94% | -13.48% |
| EBIT | -275.31% | -102.90% | 35.42% | -76.15% | 6.42% |
| EBITDA | -- | -- | 35.25% | -75.97% | 6.56% |
| EPS Basic | -118.76% | -13.27% | 96.28% | 261.95% | 50.76% |
| Normalized Basic EPS | -118.82% | -13.33% | 151.18% | 261.86% | 50.77% |
| EPS Diluted | -118.76% | -13.27% | 96.28% | 261.95% | 50.76% |
| Normalized Diluted EPS | -118.82% | -13.33% | 151.18% | 261.61% | 50.77% |
| Average Basic Shares Outstanding | 76.28% | 78.41% | 77.78% | 142.70% | 130.45% |
| Average Diluted Shares Outstanding | 76.28% | 78.41% | 77.78% | 143.05% | 130.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |